Biocorrx Inc. (BICX)
OTCQB OTCQB Primary Summary
Biocorrx Inc. (BICX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Biocorrx Inc. ever had a stock split?
Biocorrx Inc. Profile
| Biotechnology Industry | Healthcare Sector | Ms. Lourdes Felix CEO | OTCQB Exchange | US09073C2052 ISIN |
| United States Country | - Employees | - Last Dividend | 22 Jan 2019 Last Split | - IPO Date |
Overview
BioCorRx Inc. operates primarily in the United States, focusing on the development and provision of treatment programs for substance abuse and related disorders. Initially known as Fresh Start Private Management, Inc., the company underwent a rebranding to BioCorRx Inc. in January 2014. It aims to offer innovative, comprehensive solutions through its subsidiaries, targeting healthcare providers, independent licensed clinics, and licensed healthcare professionals. With its headquarters located in Anaheim, California, BioCorRx leads in distributing and licensing effective treatment solutions to combat addiction and support weight management.
Products and Services
- BioCorRx Recovery Program:
- UnCraveRx Weight Loss Management Program:
- BICX101:
- BICX104:
A non-addictive, medication-assisted treatment program designed to address substance abuse and related disorders. It combines a proprietary naltrexone implant with an inclusive counseling program, aiming to offer a comprehensive approach to recovery from addiction. This program utilizes naltrexone, an opioid antagonist, to reduce the cravings and effects of opioids and alcohol, thereby facilitating the recovery process for individuals battling substance addiction.
A forward-thinking, medically assisted weight management program that aims to reduce food cravings through medication, supplemented with on-demand virtual lifestyle support that includes fitness and nutrition guidance. This program is specifically designed to aid individuals in managing their weight more effectively by addressing the cravings that can often hinder weight loss efforts.
An innovative development by BioCorRx, BICX101 is an injectable form of naltrexone. This product is being developed as a long-acting option to combat opioid addiction and alcoholism, offering a more convenient and potentially more effective treatment alternative to daily oral naltrexone dosages. By providing a long-lasting release of medication, BICX101 aims to improve compliance and outcomes in the treatment of these challenging conditions.
Further expanding their offerings in addiction treatment solutions, BioCorRx is also developing BICX104, an implantable naltrexone device. This product is designed to deliver a constant, therapeutic level of naltrexone over an extended period, targeting opioid addiction and alcoholism. Similar to BICX101, BICX104 aims to provide an effective, long-term solution to assist individuals in maintaining their recovery from addiction.
